Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,699.38
(
0.00%
)
US TECH 100
24,035.20
(
0.08%
)
Dow Jones
46,946.41
(
0.00%
)
Brent Oil
100.06
(
1.79%
)
Bitcoin
73,900.84
(
-1.25%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 55873

Saturday, 12/08/2007 6:28:34 PM

Saturday, December 08, 2007 6:28:34 PM

Post# of 257251
MNTA’s M118 vs oral FXa inhibitors:

A poster on SI just asked why M118 is a better drug than Rivaroxaban. The answer is: it’s not better… it’s different.

M118 inhibits both FXa and FIIa (#msg-24393520), while Rivaroxaban inhibits FXa only. This makes Rivaroxaban unsuitable for use in such indications as ACS and stable angina where FIIa inhibition is obligatory.

On the other hand, for chronic prevention of DVT and chronic prevention of stoke in patients with AF, Rivaroxaban and other oral FXa inhibitors such as Apixaban enjoy the convenience of being a pill.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now